David Sinclair· PhD
Meanwhile, studies of metformin in the elderly should help convince the FDA if it works to slow aging
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Meanwhile, studies of metformin in the elderly should help convince the FDA if it works to slow aging
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
there are metformin studies which included elderly people for example the dpp the dpp by the way got a 20 funding from the nia in order to include 20 of the subjects over the age of 65 which they didn't they had 20 over the age of 60 but there's still people over the age of 65 and and their results were similar in prevention diabetes to er to younger people so it's an example but we have several other studies that tells us that metformin will still target aging even if you started it it's not it's not that the first disease canceled yeah it just means that you have a lower period to apply the brakes on
there are metformin studies which included elderly people for example the dpp the dpp by the way got a 20 funding from the nia in order to include 20 of the subjects over the age of 65 which they didn't they had 20 percent over the age of 60 but they're still people over the age of 65 and and their results were similar in prevention diabetes to uh to younger people so it's an example but we have several other studies that tells us that metformin will still target aging even if you started it